15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Alterity Therapeutics Ltd, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $10.00 to $16.00, a moderate spread. The average target of $12.67 sits 181% above the current $4.50. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees revenue growth near -35% this year and -68% next.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Alterity Therapeutics Ltd.
As of Sep, 4 of 4 firms rate ATHE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ATHE EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Alterity Therapeutics Ltd to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-0.77, growing to $-0.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $570.5K, rising to $2.3M next year.
Top analysts covering Alterity Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATHE.
#1
Jason McCarthy
Maxim Group · Rank #428
Buy
$12.00+166.7% to target
Overall win rate
32%
+ Follow
#2
AV
Adam Vogel
Craig-Hallum
Buy
$12.00+166.7% to target
Coverage
—
+ Follow
#3
DC
Debanjana Chatterjee
Jones Trading
Buy
$16.00+255.6% to target
Coverage
—
+ Follow
ATHE stock forecast FAQ
What is ATHE's average 12-month price target?+
The 3 analysts with a live target average $12.67 for Alterity Therapeutics Ltd over the next 12 months, ranging from a $16.00 high to a $10.00 low.
Is ATHE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ATHE?+
The Street-high target is $16.00 (Jones Trading), and the Street-low is $10.00 (Ladenburg Thalmann). The average of all 3 active targets is $12.67.
How many Wall Street analysts cover ATHE?+
4 analysts have an active rating on Alterity Therapeutics Ltd, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering ATHE?+
Among analysts who currently cover ATHE, Jason McCarthy of Maxim Group has the strongest overall Quantellect track record (Rank #428). Their current call is Buy with a $12.00 target.
What is Alterity Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-0.77, rising to $-0.96 the following year.
How much revenue is Alterity Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $570.5K, growing to $2.3M next year.
Have analysts been upgrading or downgrading ATHE lately?+
As of Sep, 4 of 4 firms rate ATHE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATHE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Ladenburg Thalmann
